Skip to content
DataLookout
Menu

NbTAST-01NCT07055594

A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 4 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Publications: details revised at 1 of 1 entryv4
  3. Minor Start date changed from estimate of Jul 2025 to Jul 30, 2025v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (MTD) of SOA101 for Phase I
Timeframe: from start until 3 months after the last dosing
Objective Response Rate (ORR) of SOA101 for Phase II
Timeframe: from start until 3 months after the last dosing

Secondary (4)

Area Under the Curve of SOA101 (AUC)
Maximum observed plasma concentration of SOA101 (Cmax)
Half-life of SOA101 (T1/2)
Overall Response Rate (ORR)

Arms and interventions

SOA101Experimental

Drugs: SOA101

Sites

1 site in 1 country

  • China Medical University HospitalTaichung, Taiwan